ClinicalTrials.gg
TerminatedNCT04369469Updated May 24, 2022Results posted

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

A Phase 3 interventional study of Ravulizumab and BSC in COVID-19 Severe Pneumonia, Acute Lung Injury and Acute Respiratory Distress Syndrome, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-24.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Why this study was terminated
Met futility bar at interim analysis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.

Enrollment
18th of 88
202 · median 68
Started
2020
with 13 others
Phase 3
11 of 112
1 open now
Registered
76th of 112
by date
Lead sponsor
2 of 112
Alexion Pharmaceuticals, Inc.

Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 18th largest by enrollment of the 88 interventional ones that give a count, is one of 14 that started in 2020, is one of 11 in phase 3, and was the 76th registered.

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

Browse Acute Lung Injury studies →

Open to participants now

17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Acute Lung Injury with a site in United States, or all of them as a file.
02

Study summary

This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the participants) or BSC alone (1/3 of the participants). BSC consisted of medical treatment and/or medical interventions per routine hospital practice.

03

Conditions studied

  • COVID-19 Severe Pneumonia
  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome
  • Pneumonia, Viral

Keywords

  • acute lung injury
  • acute respiratory distress syndrome
  • antibodies, monoclonal, humanized
  • COVID-19
  • hospitalization
  • pneumonia
  • severe pneumonia
  • severe acute respiratory syndrome
  • severe acute respiratory syndrome coronavirus 2
  • randomized controlled study
  • ravulizumab
  • respiratory distress syndrome, adult
  • Ultomiris
  • viral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or female participants ≥ 18 years of age and ≥ 40 kilograms at the time of providing .
  2. Confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection (for example, via polymerase chain reaction and/or antibody test) presenting as severe COVID-19 requiring hospitalization.
  3. Severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed by computed tomography or X-ray at Screening or within the 3 days prior to Screening, as part of the participant's routine clinical care.
  4. Respiratory distress requiring mechanical ventilation, which can be either invasive (requiring endotracheal intubation) or noninvasive (with continuous positive airway pressure or bilevel positive airway pressure).
  5. Female participants of and male participants with female partners of childbearing potential must follow protocol specified guidance for avoiding pregnancy for 8 months after treatment with the study drug.

Exclusion criteria

Exclusion Criteria:

  1. Participant was not expected to survive for more than 24 hours.
  2. Participant was on invasive mechanical ventilation with intubation for more than 48 hours prior to Screening.
  3. Severe pre-existing cardiac disease (that is, Class 3 or Class 4, acute coronary syndrome or persistent ventricular tachyarrhythmias).
  4. Participant had an unresolved Neisseria meningitidis infection.
  5. Used the following medications and therapies:

    • Current treatment with a complement inhibitor or
    • Intravenous immunoglobulin within 4 weeks prior to randomization on Day 1
  6. Treatment with therapy in a clinical study within 30 days before randomization, or within 5 half-lives of that investigational therapy, whichever was greater. Exceptions:

    • Investigational therapies were allowed if received as part of BSC through an expanded access protocol or emergency approval for the treatment of COVID-19.
    • Investigational antiviral therapies (such as remdesivir) were allowed even if received as part of a clinical study.
  7. Female participants who were breastfeeding or who have a positive pregnancy test result at Screening.
  8. History of to any ingredient contained in the study drug, including hypersensitivity to murine proteins.
  9. Participant who was not currently vaccinated against Neisseria meningitidis, unless the participant agrees to receive prophylactic treatment with appropriate antibiotics for at least 8 months after the last infusion of study drug or until at least 2 weeks after the participant receives vaccination against Neisseria meningitidis.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Group 1 - Ravulizumab + BSC

    Biological: Ravulizumab · Other: BSC

  • Other
    Group 2 - BSC alone

    Other: BSC

Interventions

  • BiologicalRavulizumab

    Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.

    Also known as: Ultomiris, ALXN1210

  • OtherBSC

    Participants received medications, therapies, and interventions per standard hospital treatment protocols.

06

What researchers measure

Primary outcomes

  1. Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29

    Survival (based on all-cause mortality) in Participants in the ITT Population at Day 29 was analyzed. The result for the survival was estimated survival combined over all imputations.

    Time frame: Day 29

Secondary outcomes

  1. Number Of Days Free Of Mechanical Ventilation At Day 29

    The number of days free of mechanical ventilation was defined as the total number of days from Day 1 to Day 29 without invasive or non-invasive mechanical ventilation.

    Time frame: Day 29

  2. Number of Days the Participants Were Alive and Not in ICU

    The number of days that the participants were alive and not in the ICU from Day 1 through Day 29 are presented.

    Time frame: Day 1 through Day 29

  3. Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29

    Baseline was defined as the last available assessment on or before Day 1 for all participants. Participants were evaluated using the SOFA score, an assessment tool that included a review of 6 organ systems: respiratory, renal, hepatic, cardiac, coagulation, and central nervous system. Each organ system was scored from 0 to 4 points using the worst value observed within the previous 24 hours. The total score ranged from 0 to 24, with a higher score indicating a worse condition.

    Time frame: Baseline, Day 29

  4. Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29

    Oxygenation was measured using the SpO2 and the amount of supplemental oxygen as measured by the FiO2 received by taking the ratio of these 2 measures at the same time point.

    Time frame: Baseline, Day 29

  5. Number of Days the Participants Were Alive and Not in the Hospital

    The number of days that the participants were alive and not in the hospital from Day 1 through Day 29 are presented.

    Time frame: Day 1 through Day 29

  6. Estimated Number of Participants Alive At Up To Day 60 and At Up To Day 90

    For this analysis, 2 participants in Group 1 (Ravulizumab + BSC) and 1 participant in Group 2 (BSC Alone) were censored at Day 90. The estimated number of participants alive for this analysis was calculated using the method of Kaplan and Meier (KM) and compared using a log-rank test stratified by intubated or not intubated on Day 1 as a sensitivity analysis. This Outcome Measure was designed to project an estimate of how many participants would be alive and not the actual number of alive participants. All-Cause Mortality data is provided in the Adverse Events Section.

    Time frame: Up to Day 60 and Up to Day 90

  7. Serum Ravulizumab Concentrations Prior to Dosing on Day 1 and Day 29

    Results are reported in micrograms/milliliter (μg/mL).

    Time frame: Day 1 and Day 29

  8. Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29

    Time frame: Baseline, Day 29

  9. Change From Baseline In Terminal Complement Complex C5b-9 At Day 29

    Time frame: Baseline, Day 29

07

Results

Posted May 24, 2022
Limitations and caveats
Enrollment of participants was paused on 13-Jan-2021. At that time, 202 participants had been randomized. An interim analysis for efficacy and futility was conducted on data from the first 122 participants who completed the Primary Evaluation Period. The analysis showed that the study met the prespecified stopping criteria for futility. After review of all participant data, Alexion terminated the study on 01-Sep-2021.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Started13567
Intent to treat (itt) population13566
Pharmacokinetic (pk)12752
Safety population12767
Completed12558
Not completed109
Withdrew: Lost to follow-up24
Withdrew: Physician decision21
Withdrew: Withdrawal by subject23
Withdrew: Adverse event10
Withdrew: Did not meet inclusion/exclusion criteria20
Withdrew: Not qualified due to history of anaphylaxis10
Withdrew: Unable to provide consent01

Outcome measures

PrimarySurvival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29

Survival (based on all-cause mortality) in Participants in the ITT Population at Day 29 was analyzed. The result for the survival was estimated survival combined over all imputations.

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29
Percentage of participantsGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 2957.659.7
Statistical analysis
  • Group 1 - Ravulizumab + BSC vs Group 2 - BSC Alone · Mantel Haenszel · p = 0.6059 (One-sided Mantel-Haenszel test of the difference in two proportions stratified by intubated or not intubated on Day 1 and a family-wise Type I error of 0.025.) · Risk difference (rd): -0.0205 · 95% CI -0.1703 to 0.1293Two-sided 95% confidence interval using the Sato variance estimator, combined overall imputations.
SecondaryNumber Of Days Free Of Mechanical Ventilation At Day 29

The number of days free of mechanical ventilation was defined as the total number of days from Day 1 to Day 29 without invasive or non-invasive mechanical ventilation.

Time frame:
Day 29
Reported as:
Least squares mean · Days
Number Of Days Free Of Mechanical Ventilation At Day 29
DaysGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Number Of Days Free Of Mechanical Ventilation At Day 296.79 (4.79 to 8.80)6.81 (4.19 to 9.43)
SecondaryNumber of Days the Participants Were Alive and Not in ICU

The number of days that the participants were alive and not in the ICU from Day 1 through Day 29 are presented.

Time frame:
Day 1 through Day 29
Reported as:
Least squares mean · Days
Number of Days the Participants Were Alive and Not in ICU
DaysGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Number of Days the Participants Were Alive and Not in ICU6.09 (4.31 to 7.87)6.71 (4.38 to 9.03)
SecondaryChange From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29

Baseline was defined as the last available assessment on or before Day 1 for all participants. Participants were evaluated using the SOFA score, an assessment tool that included a review of 6 organ systems: respiratory, renal, hepatic, cardiac, coagulation, and central nervous system. Each organ system was scored from 0 to 4 points using the worst value observed within the previous 24 hours. The total score ranged from 0 to 24, with a higher score indicating a worse condition.

Time frame:
Baseline, Day 29
Reported as:
Mean · Units on a scale
Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29
Units on a scaleGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29-2.0 ± 6.25-4.5 ± 4.90
SecondaryChange From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29

Oxygenation was measured using the SpO2 and the amount of supplemental oxygen as measured by the FiO2 received by taking the ratio of these 2 measures at the same time point.

Time frame:
Baseline, Day 29
Reported as:
Mean · ratio
Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29
ratioGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 2962.5 ± 112.43134.0 ± 104.35
SecondaryNumber of Days the Participants Were Alive and Not in the Hospital

The number of days that the participants were alive and not in the hospital from Day 1 through Day 29 are presented.

Time frame:
Day 1 through Day 29
Reported as:
Least squares mean · Days
Number of Days the Participants Were Alive and Not in the Hospital
DaysGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Number of Days the Participants Were Alive and Not in the Hospital3.02 (1.76 to 4.29)3.47 (1.83 to 5.12)
SecondaryEstimated Number of Participants Alive At Up To Day 60 and At Up To Day 90

For this analysis, 2 participants in Group 1 (Ravulizumab + BSC) and 1 participant in Group 2 (BSC Alone) were censored at Day 90. The estimated number of participants alive for this analysis was calculated using the method of Kaplan and Meier (KM) and compared using a log-rank test stratified by intubated or not intubated on Day 1 as a sensitivity analysis. This Outcome Measure was designed to project an estimate of how many participants would be alive and not the actual number of alive participants. All-Cause Mortality data is provided in the Adverse Events Section.

Time frame:
Up to Day 60 and Up to Day 90
Reported as:
Count of participants · Participants
Estimated Number of Participants Alive At Up To Day 60 and At Up To Day 90
ParticipantsGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Day 606029
Day 904920
SecondarySerum Ravulizumab Concentrations Prior to Dosing on Day 1 and Day 29

Results are reported in micrograms/milliliter (μg/mL).

Time frame:
Day 1 and Day 29
Reported as:
Mean · μg/mL
Serum Ravulizumab Concentrations Prior to Dosing on Day 1 and Day 29
μg/mLGroup 1 - Ravulizumab + BSC
Day 1 (predose)0.00 ± 0.00
Day 29 (predose)231.35 ± 149.741
SecondaryChange From Baseline In Serum Free Complement Component 5 Concentrations At Day 29
Time frame:
Baseline, Day 29
Reported as:
Mean · μg/mL
Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29
μg/mLGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29-156.31 ± 61.59921.79 ± 67.918
SecondaryChange From Baseline In Terminal Complement Complex C5b-9 At Day 29
Time frame:
Baseline, Day 29
Reported as:
Mean · ug/L
Change From Baseline In Terminal Complement Complex C5b-9 At Day 29
ug/LGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Change From Baseline In Terminal Complement Complex C5b-9 At Day 29-133.23 ± 202.070-277.21 ± 604.742

Adverse events

Collected over Day 1 through Day 90. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 - Ravulizumab + BSC55/135 (40.7%)79/127 (62.2%)97/127 (76.4%)
Group 2 - BSC Alone25/66 (37.9%)38/67 (56.7%)49/67 (73.1%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
Multiple organ dysfunction syndromeGeneral disorders14/1276/67
Septic shockInfections and infestations13/1273/67
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders12/1275/67
Respiratory failureRespiratory, thoracic and mediastinal disorders5/1275/67
Acute respiratory failureRespiratory, thoracic and mediastinal disorders6/1274/67
COVID-19 pneumoniaInfections and infestations7/1270/67
HypoxiaRespiratory, thoracic and mediastinal disorders4/1273/67
Cardiac arrestCardiac disorders4/1272/67
PneumoniaInfections and infestations4/1271/67
PneumothoraxRespiratory, thoracic and mediastinal disorders4/1272/67
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGroup 1 - Ravulizumab + BSCGroup 2 - BSC Alone
HypotensionVascular disorders16/1278/67
Deep vein thrombosisVascular disorders14/1272/67
AnaemiaBlood and lymphatic system disorders13/1274/67
Atrial fibrillationCardiac disorders12/1275/67
PyrexiaGeneral disorders10/1276/67
HyperkalaemiaMetabolism and nutrition disorders8/1276/67
HypernatraemiaMetabolism and nutrition disorders11/1273/67
Acute kidney injuryRenal and urinary disorders9/1275/67
ConstipationGastrointestinal disorders5/1275/67
HypertensionVascular disorders9/1273/67

Baseline characteristics

The ITT Population consisted of all randomized participants. Participants were analyzed as randomized.

Age, Continuous
Age, Continuous(years)Group 1 - Ravulizumab + BSCGroup 2 - BSC AloneTotal
Mean63.2 ± 13.2363.5 ± 12.4063.3 ± 12.93
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 - Ravulizumab + BSCGroup 2 - BSC AloneTotal
Female392362
Male9643139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Group 1 - Ravulizumab + BSCGroup 2 - BSC AloneTotal
Not Hispanic or Latino10046146
Hispanic or Latino271138
Missing/Unknown7512
Not reported145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Group 1 - Ravulizumab + BSCGroup 2 - BSC AloneTotal
White7240112
Black or African American20727
Missing/Unknown17522
Other13518
Asian9615
Not Reported426
American Indian or Alaska Native101
Native Hawaiian or Other Pacific Islander011
08

Study locations

39 sites
  • Central Arkansas Veterans Healthcare System
    Little Rock, Arkansas 72205, United States
  • LAC/USC Health Center
    Los Angeles, California 90033, United States
  • UC Irvine Medical Center
    Orange, California 92868, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • University of Florida
    Jacksonville, Florida 32209, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Norton Healthcare
    Louisville, Kentucky 40241, United States
  • Baltimore VA Medical Center
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic Health System
    Mankato, Minnesota 56001, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • NYU Langone Health Center
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Westchester Medical Center
    Valhalla, New York 10595, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Baptist Memorial Hospital
    Memphis, Tennessee 38120, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Mayo Clinic Health System in Eau Claire
    Eau Claire, Wisconsin 54703, United States
  • Mayo Clinic Health System
    La Crosse, Wisconsin 54601, United States
  • Hôpital Raymond Poincaré
    Garches, Hauts De Seine 92380, France
  • Hôpital Henri Mondor
    Créteil, Val De Marne 94000, France
  • Hôpital Bicêtre
    Le Kremlin-Bicêtre cedex, Val De Marne 94275, France
  • Medical Hospital, Tokyo Medical and Dental University
    Bunkyō-Ku, Tokyo-To 113-8519, Japan
  • Jikei University Hospital
    Minato-Ku, Tokyo 105-8471, Japan
  • Tokyo Medical University Hospital
    Shinjuku-Ku, Tokyo 160-0023, Japan
  • Hospital Universitari de Bellvitge
    L'Hospitalet De Llobregat, Barcelona 08907, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • King's College Hospital
    London, Greater London SE5 9RS, United Kingdom
  • Hammersmith Hospital
    London, Greater London W12 0HS, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, Merseyside L7 8XP, United Kingdom
  • Queen Elizabeth Hospital
    Birmingham, West Midlands B15 2TH, United Kingdom
  • St James's University Hospital
    Leeds, West Yorkshire LS9 7TF, United Kingdom
09

References and documents

Publications

  • WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance, 28 January 2020.
  • McEneny-King AC, Monteleone JPR, Kazani SD, Ortiz SR. Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019. Infect Dis Ther. 2021 Jun;10(2):1045-1054. doi: 10.1007/s40121-021-00425-7. Epub 2021 Apr 7. PubMed 33826106 ↗
  • Smith K, Pace A, Ortiz S, Kazani S, Rottinghaus S. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z. PubMed 32660611 ↗
  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗
  • Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight. 2020 Aug 6;5(15):e140711. doi: 10.1172/jci.insight.140711. PubMed 32554923 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Clinical study report

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Feb 2021, 8 months.

Results were first posted in May 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2020
First posted
Apr 30, 2020
StartActual
May 10, 2020
Primary completionActual
Feb 8, 2021
CompletionActual
Apr 8, 2021
Results first posted
May 24, 2022
Last update
May 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04369469
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
May 10, 2020
Primary completion
Feb 8, 2021
Completion
Apr 8, 2021
Results posted
May 24, 2022
Last update
May 24, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion